VRC– Afrigen Research Collaboration

Jason Gall, PhD
Director, Vaccine Production Program Lab & Strategic Planning
July 8, 2022
Vaccine Research Center (VRC, NIAID)

- Founded: HIV Vaccine
- Ebola/Marburg
- Influenza
- Respiratory Syncytial Virus
- Chikungunya virus
- Equine encephalitis viruses
- SARS-CoV2, MERS-CoV, SARS
- Tuberculosis
- Malaria
- West Nile virus, Zika

Basic Research — Clinical Trials
VRC: Discovery, Development, & Clinical Evaluation

- Basic Research
- Immune Assays
- Clinical Trials
- Process Development
- cGMP Manufacture
VRC Investigational Product Capabilities

Commercially Licensed Platforms

- Recombinant Proteins (HBV)
- Recombinant Virus Like Particles (HPV)
- Viral Vectors (VSV-Ebo)
- Designer Proteins (RSV)
- Genetic DNA (WNV)
- Genetic RNA (SARS-CoV-2)
- Protein Nanoparticles
- CHO Cell Production of Antibodies
- Monoclonal
- Multi-specific
Industry Partnerships

- Research collaborations increase out-licensing activity
In Conclusion

• VRC has long history of research collaborations
• Collaborating with industry partners early in the research process improves product-related outcomes
  – Significant rise in commercial development licenses
  – Four US FDA approved products with VRC technology
• Afrigen is the VRC’s first South African industry partner